Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q2 2026 › vs Q2 2025
Jazz Pharmaceuticals (JAZZ) Q2 2026 vs Q2 2025 (year over year)
Jazz Pharmaceuticals's revenue rose $163M (+16%) from $1.0B in Q2 2025 to $1.2B in Q2 2026. The biggest changes: Product sales, net +$107M (+10%); Modeyso +$47.7M (96×). Operating margin 20.5% against -65.6% (+86.2 pts).
Jazz Pharmaceuticals, Q2 2026: revenue $1.2B (+16% year over year), operating margin 20.5%, net earnings $193M, operating cash flow $416M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 20.5% | -65.6% | +86.2 pts |
| Net margin | 16.0% | -68.7% | +84.7 pts |
| Free cash flow margin | 32.9% | 7.3% | +25.6 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Xywav | $471M | $415M | $55.9M | +13% |
| Epidiolex/Epidyolex | $292M | $252M | $40.4M | +16% |
| Zepzelca | $106M | $74.5M | $31.3M | +42% |
| Rylaze/Enrylaze | $99.5M | $101M | −$1.2M | -1% |
| Defitelio/defibrotide | $62.0M | $48.1M | $13.9M | +29% |
| Product and Services, Royalties and Contract Revenue | $52.2M | $60.1M | −$7.9M | -13% |
| High-sodium oxybate AG royalty revenue | $42.2M | $54.1M | −$11.9M | -22% |
| Vyxeos | $31.4M | $44.9M | −$13.5M | -30% |
| Product sales, net | $1.2B | $1.0B | $107M | +10% |
| Modeyso | $48.2M | $500K | $47.7M | 96× |
| Revenue | $1.2B | $1.0B | $163M | +16% |
| Operating profit | $248M | −$686M | $935M | — |
| Costs & expenses | $960M | $1.7B | −$772M | -45% |
| Pre-tax earnings | $211M | −$736M | $947M | — |
| Other expense, net | $37.2M | $49.2M | −$12.0M | -24% |
| Research & development | $208M | $190M | $17.6M | +9% |
| SG&A | $389M | $358M | $30.8M | +9% |
| Other operating costs | $363M | $1.2B | −$820M | -69% |
| Net earnings | $193M | −$718M | $911M | — |
| Income tax | $18.1M | −$17.2M | $35.3M | — |
| Depreciation & amortization | $179M | $174M | $5.1M | +3% |
| Share-based compensation | $73.3M | $64.5M | $8.8M | +14% |
| Working capital & other | $29.5M | −$569M | $598M | — |
| Operating cash flow | $416M | $88.8M | $327M | +368% |
| Free cash flow (OCF − capex) | $398M | $75.9M | $322M | +424% |
| Capital expenditures | $18.1M | $12.9M | $5.2M | +40% |
Questions
How much did Jazz Pharmaceuticals's revenue grow year over year in Q2 2026?
Jazz Pharmaceuticals's revenue rose $163M (+16%) from $1.0B in Q2 2025 to $1.2B in Q2 2026.
What drove Jazz Pharmaceuticals's revenue change in Q2 2026?
Product sales, net +$107M (+10%); Modeyso +$47.7M (96×).